1. Home
  2. SUPV vs ACRS Comparison

SUPV vs ACRS Comparison

Compare SUPV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Supervielle S.A. each Representing five Class B shares

SUPV

Grupo Supervielle S.A. each Representing five Class B shares

HOLD

Current Price

$8.69

Market Cap

770.4M

Sector

Finance

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$6.17

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPV
ACRS
Founded
1887
2012
Country
Argentina
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
770.4M
868.5M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
SUPV
ACRS
Price
$8.69
$6.17
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$13.00
$10.20
AVG Volume (30 Days)
662.2K
1.6M
Earning Date
05-26-2026
05-07-2026
Dividend Yield
2.19%
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
$86.20
N/A
Revenue Next Year
$25.12
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.54
$1.74
52 Week High
$13.55
$6.60

Technical Indicators

Market Signals
Indicator
SUPV
ACRS
Relative Strength Index (RSI) 50.77 48.86
Support Level $7.70 $5.64
Resistance Level $8.92 $6.56
Average True Range (ATR) 0.44 0.31
MACD 0.12 -0.06
Stochastic Oscillator 77.27 26.23

Price Performance

Historical Comparison
SUPV
ACRS

About SUPV Grupo Supervielle S.A. each Representing five Class B shares

Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: